Seronegative celiac disease: when antibodies are negative but the biopsy is not
Short answer
Seronegative celiac disease is celiac disease diagnosed despite negative celiac antibodies, after other causes of villous atrophy have been excluded13. The Paris consensus and the European guideline between them ask for four things:
- Villous atrophy on a correctly oriented duodenal biopsy1, with negative celiac antibodies13.
- Other causes of villous atrophy excluded, such as infections and iatrogenic (treatment-related) causes2.
- A celiac-compatible HLA type, since a negative HLA result excludes it3.
- A clinical and histological response to a gluten-free diet4.
Part of Celiac diagnosis, testing and gluten sensitivity, 25 guides

Key points
- The European guideline calls it rare, about 2%–5% of celiac cases5; Coeliac UK says research suggests 2–3%6.
- Before the label is used, the European guideline asks for total IgA to be measured alongside the first antibody test7, notes that seronegative celiac disease can be seen in people who reduced their gluten intake before testing8 and lists other conditions that cause the same biopsy finding9.
- Negative antibodies with villous atrophy are not always celiac disease: in one study's 31 cases of flat mucosa with negative antibodies, 45% were celiac disease and the others included giardiasis, common variable immunodeficiency and autoimmune enteropathy10.
- HLA typing is used when the picture is unclear: the European guideline recommends it in seronegative cases11.
- The European guideline cites the clinical complexity and poor outcomes of patients with seronegative villous atrophy and says referral to a tertiary centre should be considered12.
What does seronegative celiac disease mean?
“Seronegative” means the blood antibody tests for celiac disease came back negative13. The European guideline defines seronegative celiac disease (SNCD) by a clinical and histological response to a gluten-free diet despite negative antibodies, in people with HLA-DQ2 or HLA-DQ8, after other causes of villous atrophy are excluded13. The Paris consensus was drawn up by an international task force of 13 gastroenterologists from six countries14.
Four terms sound alike and are not the same thing.
| Term | What it describes |
|---|---|
| Seronegative villous atrophy (SNVA) | A finding: malabsorption, negative celiac serology and villous atrophy on a duodenal biopsy15. |
| Seronegative celiac disease | A diagnosis made after other causes of villous atrophy are excluded13. |
| Celiac disease with IgA deficiency | Positive IgG-based tests and villous atrophy; Coeliac UK says these patients are not considered to have seronegative celiac disease16. |
| Non-coeliac enteropathy | Chronic enteropathy with villous atrophy and negative celiac antibodies that is unrelated to gluten ingestion48; the Paris consensus says patients with it are frequently misdiagnosed as seronegative celiac disease17. |
Villous atrophy alone does not settle it: Coeliac UK notes it is not specific to celiac disease and is seen in other conditions, including giardiasis, inflammatory conditions and certain medications18.
Estimates differ by source. The European guideline gives approximately 2%–5% of all celiac cases5. Coeliac UK says research suggests seronegative celiac disease accounts for 2–3% of celiac disease and around a third of patients with seronegative villous atrophy6.
What is checked first: gluten intake, total IgA and the samples
The Paris consensus starts by checking how the tests were done21.
Was gluten in the diet?
The European guideline recommends testing while the person is on a gluten-containing diet7. NIDDK says doctors do not recommend starting a gluten-free diet before diagnostic testing, because the diet can affect test results19. The ESsCD guideline notes that seronegative celiac disease can be seen in people who reduced their gluten intake before testing8.
The Paris consensus goes further. It treats people who are negative because they were already on a gluten-free diet or on immunosuppressive therapy at the time of testing as conventional celiac disease, not seronegative20. Its first step is to rule out sampling, collection or processing errors in the blood or the biopsy, and to confirm the diet was not gluten-restricted before endoscopy21.
Our guide to how a gluten challenge works covers testing while eating gluten in more detail.
Was total IgA measured?
The European guideline asks for total IgA to be measured at the same time as the first antibody test, to exclude IgA deficiency7. ACG says that if IgA deficiency is present, an IgG serology should be measured22. Coeliac UK explains that some people with celiac disease do not make the usual antibodies, which is called IgA deficiency23.
IgG tests have limits. The European guideline says that, because of their lower sensitivity, a negative IgG result does not exclude the diagnosis, and that in people with signs of malabsorption an upper endoscopy with duodenal biopsies should be done whatever the IgG result is24. Our guide to low total IgA and celiac disease covers that branch.
Does the biopsy decision depend on the antibodies?
ACG says symptomatic patients whose pretest suspicion is high should undergo upper endoscopy with duodenal biopsy irrespective of serologic results, citing the imperfect sensitivity of serology and the possibility of seronegative celiac disease25. Coeliac UK reports that NICE and BSG guidelines recommend referral to a gastrointestinal specialist for further assessment when the serology is negative but celiac disease is still clinically suspected26.
In the other direction, the European guideline says that negative serology with a Marsh 1 biopsy makes celiac disease unlikely and that other causes should be sought27. Our guide to reading a celiac biopsy report explains the grading.
Which other conditions cause the same biopsy finding?
The European guideline lists the causes of villous atrophy that are not celiac disease. The table follows its Table 3.
| Category | Examples listed |
|---|---|
| Infections | Giardia, tuberculosis, Whipple's disease, small-bowel bacterial overgrowth, tropical sprue9 |
| Medicines and treatments | NSAIDs, angiotensin receptor blockers such as olmesartan and losartan, mycophenolate mofetil, methotrexate, colchicine, chemotherapy, immune-checkpoint inhibitors9 |
| Malignancies and lymphomas | Including enteropathy-associated T-cell lymphoma9 |
| Other pathologies | Crohn's disease, collagenous sprue, amyloidosis9 |
| Immunodeficiency | HIV/AIDS, common variable immunodeficiency, IgA deficiency9 |
| Autoimmune disorders | Autoimmune enteropathy, eosinophilic gastroenteritis9 |
| Graft-related | Graft versus host disease9 |
| Idiopathic | Used when no cause is found despite extensive investigation9 |
The Paris consensus lists what has to be excluded before the seronegative label is used: normal immunoglobulin levels, negative enterocyte antibodies, negative stool parasite, HIV and tuberculosis testing, no iatrogenic cause for the atrophy, and no history of travelling to or living in the tropics2. It adds that telling seronegative celiac disease apart from non-coeliac enteropathy matters, in part to avoid an unnecessary lifelong gluten-free diet28.
Medicines on the list are examples the guideline names as possible causes. Whether a medicine matters in a given case is for the prescriber and the gastroenterologist to decide.
In a 2013 series from one tertiary referral centre (summarised in the table below), some patients first labelled unclassified were later found to have villous atrophy associated with olmesartan use30.
What do published series report?
Each figure below comes from one centre or one study and is not directly comparable with the others; the definitions and the patients differ.
| Series | What it found |
|---|---|
| Volta et al., 2016 | Of 810 celiac diagnoses, fourteen met the criteria for seronegative celiac disease (antibody negativity, villous atrophy, HLA-DQ2/DQ8 positivity and improvement on a gluten-free diet)31. Among 31 cases of flat mucosa with negative antibodies, 45% were celiac disease, 20% giardiasis, 16% common variable immunodeficiency and 10% autoimmune enteropathy10. |
| UK centre, as reported by Coeliac UK | Of 200 adults with negative antibodies but villous atrophy followed over 15 years, 62 (31%) had seronegative celiac disease32. |
| Schiepatti et al., 2021, multicentre | Of 227 patients previously diagnosed with seronegative celiac disease, the diagnosis was confirmed in 84, celiac disease with IgA deficiency in 48, and excluded in 5533. The lack of a follow-up biopsy precluded a diagnosis in 40 patients34. |
| DeGaetani et al., 2013, tertiary referral centre | 72 adults with villous atrophy and negative serology: the most common diagnoses were seronegative celiac disease, medication-related atrophy and unclassified sprue29. |
Two patterns recur. First, seronegative celiac disease was linked to a more severe presentation: Volta's group found a higher median age at diagnosis and more malabsorption, autoimmune disorders and severe villous atrophy than in seropositive disease35, and Schiepatti's group found, for true seronegative celiac disease compared with seropositive disease, more severe symptoms and a higher risk of complications and mortality36. Second, labels were revised: in the Schiepatti cohort the diagnosis was excluded in 55 of 227 patients who had been given it33.
Schiepatti's conclusion is that the data argue against over-reliance on serology and support strict clinical and histologic follow-up in seronegative celiac disease37. The European guideline adds that patients with the condition have a worse prognosis and a more severe clinical phenotype than seropositive patients38.
What do HLA typing and a gluten challenge add?
HLA-DQ2 and DQ8
The European guideline does not use HLA typing routinely in the first diagnosis, because it has a poor positive predictive value and a high negative predictive value39. It does recommend typing when the diagnosis is uncertain, including seronegative cases11.
The reason is the negative result. The Paris consensus says that, although up to 30%–40% of people in Caucasian populations carry HLA-DQ2 or DQ8, a negative HLA typing excludes seronegative celiac disease3. ACG says the same of celiac disease in general: if the haplotype test is negative, celiac disease is ruled out40. NIDDK adds that having DQ2 or DQ8 alone does not mean a person has celiac disease41. Our guide to celiac genetic testing covers the test in more detail.
Gluten challenge
In equivocal cases, the Paris consensus says reintroducing gluten can be necessary to bring back the intestinal damage and symptoms and so confirm the diagnosis, and that the dose and duration of a challenge have not been standardised42. The European guideline says a challenge is required when someone suspected of celiac disease reduced or stopped gluten before a proper evaluation43. Whether to start a challenge is a decision for the treating gastroenterologist.
Why is the response to the diet read so carefully?
With no positive antibody test to confirm it, the diet response carries much of the diagnosis. The European guideline says that after other causes are excluded, the diagnosis should rest on the clinical and histological response to a gluten-free diet in people with HLA-DQ2 or DQ84. The Paris criteria likewise require villous atrophy that recovers on a gluten-free diet1, and require the investigations to be done before the diet or immunosuppressive therapy starts, because those may lead to a false negative serology44.
That is why a repeat biopsy features in the literature. Coeliac UK's clinician page says a follow-up biopsy may be considered after 1–2 years on the diet, or sooner in severe illness, to assess the response45. In the Schiepatti cohort, the lack of a follow-up biopsy was the reason 40 patients could not be given the diagnosis34. Our guide to follow-up testing after a celiac diagnosis covers the follow-up step.
Questions people bring to the appointment
These are prompts drawn from the checks above, not a checklist for diagnosing yourself: NIDDK says celiac disease is not diagnosed from symptoms alone47. The answers belong to a gastroenterologist.
- Was I eating gluten, and for how long, before the blood test and the biopsy?
- Was my total IgA measured with the antibody test, and if it was low, were IgG-based tests done?
- Was the biopsy sampled and processed in a way that rules out sampling or orientation errors?
- Have infections, medicines and immune conditions been looked at as other causes of the damage?
- Has HLA-DQ2/DQ8 typing been done, and what does the result change?
- If the label is seronegative celiac disease, what follow-up biopsy and review are planned, and when?
- Is a referral to a centre that sees these cases an option?
Whose guidance this page draws on
Most of the detailed criteria on this page come from European and international sources: the European Society for the Study of Coeliac Disease guideline (2025) and the Paris consensus (Gut, 2022). ACG 2023 and NIDDK are the US sources used; Coeliac UK is a UK charity.
Questions people ask
Can you have celiac disease with a negative blood test?
Coeliac UK says it is possible. If you were not eating gluten at the time of the test, the result may be inaccurate46, and some people with celiac disease do not make the usual antibodies because of IgA deficiency23. A separate group has true seronegative celiac disease, diagnosed only after other causes are excluded13.
More in Celiac diagnosis, testing and gluten sensitivity
Low total IgA and celiac disease: which tests guidelines name insteadWhy very low total IgA can hide celiac disease on the usual tTG-IgA test, which IgG-based tests guidelines name instead, and what a clinic should cover.
Celiac Blood Tests: What tTG-IgA, Total IgA, DGP and EMA Each CheckWhat tTG-IgA, total IgA, EMA and DGP check, why total IgA is drawn with tTG-IgA, when back-up tests are used, and why gluten stays in the diet first.
Marsh 1 on a biopsy report with negative celiac blood tests: what the guidelines sayWhat Marsh 1 or lymphocytic duodenosis means when celiac antibodies are negative, which other causes sources list, and what guidelines say comes next.
Positive celiac blood test but a normal biopsy: what doctors call potential celiac diseaseWhat celiac guidelines say when antibodies are positive but the biopsy looks normal: potential celiac disease, other causes, and the follow-up described.
Reading a tTG-IgA result: cutoffs, borderline results and lab differencesWhat the number, cutoff and flag on a tTG-IgA report mean, why labs differ, and where guidelines draw the line at 10 times the upper limit of normal.
Questions to bring to a gastroenterologist when celiac disease is suspectedQuestions for a celiac disease appointment: what to bring, what the sources say about diet before testing, and what to ask about the biopsy and follow-up.
All 25 guides in Celiac diagnosis, testing and gluten sensitivity
Related guides
Villous atrophy that is not celiac disease: other causes doctors checkConditions and medicines that clinical consensus and reviews name as causes of flat small-bowel villi besides celiac disease, and what the work-up covers.
How a gluten challenge works before celiac testingWhat named celiac sources say about the amount and length of a gluten challenge before testing, side by side, and why a clinician plans it.
Celiac genetic testing: what HLA-DQ2 and DQ8 results can and cannot tell youWhat HLA-DQ2 and DQ8 typing checks for, how NIDDK, ACG, ESPGHAN and WGO read a negative or positive result, and where the guidelines place the test.
Follow-up testing after a celiac diagnosis: what the guidelines listWhat celiac guidelines and charities list for follow-up: antibody checks, repeat biopsy, nutrient tests, and what is checked if symptoms continue.
Sources
- [1, 2, 3, 14, 17, 20, 21, 28, 42, 44, 48] Gut (BMJ), Nomenclature and diagnosis of seronegative coeliac disease and chronic non-coeliac enteropathies in adults: the Paris consensus (Schiepatti et al., 2022), checked Nov 17, 2026.
- [4, 5, 7, 8, 9, 11, 12, 13, 15, 24, 27, 38, 39, 43] European Society for the Study of Coeliac Disease, ESsCD 2025 Updated Guidelines on the Diagnosis and Management of Coeliac Disease in Adults. Part 1: Diagnostic Approach, checked Nov 17, 2026.
Read on 2026-11-17: Table 3, “The differential diagnosis of non-coeliac villous atrophy”, lists infections (viral or bacterial enteritis, giardia, tuberculosis, Mycobacterium avium complex, Whipple's disease, small-bowel bacterial overgrowth, tropical sprue); medicines and treatments (NSAIDs, angiotensin type 1 receptor blockers such as olmesartan and losartan, mycophenolate mofetil, methotrexate, colchicine, chemotherapy, radiation enteritis, small-bowel transplant, immune-checkpoint inhibitors); malignancies and lymphomas (including enteropathy-associated T-cell lymphoma); other pathologies (Crohn's disease, collagenous sprue, amyloidosis); immunodeficiency (HIV/AIDS, common variable immunodeficiency, IgA deficiency); autoimmune disorders (autoimmune enteropathy, eosinophilic gastroenteritis); graft-related disorders (graft versus host disease); and an idiopathic group, “When no causes have been found despite extensive investigations”.
- [6, 16, 18, 26, 32, 45] Coeliac UK, Seronegative coeliac disease (healthcare professionals), checked Nov 17, 2026.
- [10, 31, 35] Digestive and Liver Disease, Seronegative celiac disease: Shedding light on an obscure clinical entity (Volta et al., 2016; abstract), checked Nov 17, 2026.
- [19, 41, 47] National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Diagnosis of Celiac Disease, checked Nov 17, 2026.
- [22, 25, 40] American College of Gastroenterology, ACG Clinical Guidelines Update: Diagnosis and Management of Celiac Disease (Rubio-Tapia et al., 2023), checked Nov 17, 2026.
- [23, 46] Coeliac UK, Blood tests and biopsy, checked Nov 17, 2026.
- [29, 30] American Journal of Gastroenterology, Villous atrophy and negative celiac serology: a diagnostic and therapeutic dilemma (DeGaetani et al., 2013; abstract), checked Nov 17, 2026.
- [33, 34, 36, 37] Alimentary Pharmacology & Therapeutics, Clinical classification and long-term outcomes of seronegative coeliac disease: a 20-year multicentre follow-up study (Schiepatti et al., 2021; abstract), checked Nov 17, 2026.